Kwon, Youngjoo Professor

Pharmaceutical Sciences/Industrial Pharmaceutical Science/Division of Pharmacy

권영주 프로필 사진
Youngjoo Kwon, a Professor at College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, majored in Department of Chemistry, University of Houston for Ph.D. and continued Postdoctoral Associate at Department of Biochemistry and Molecular biology, Baylor College of Medicine. She has currently focused on developing chemotherapeutics targeting HER2 positive cancers and triple negative breast cancers. She has been also trying to understand the isoform-specific function of neuro-degenerative disease-related enzyme and to develop the isoform-specific inhibitors. She published more than 150 SCI(E) papers and registered 11 international and domestic patents.
  • Director, Drug Development Research Core Center
  • Pharmaceutical Science Building B #101
  • 02-3277-4653
  • Office hours
    • 월 4-6시
Research Record
  • A novel A2a adenosine receptor inhibitor effectively mitigates hepatic fibrosis in a metabolic dysfunction-associated steatohepatitis mouse model International Journal of Biological Sciences, 2024, v.20 no.5, 1855-1870
    SCIE Scopus dColl.
  • Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy ACS Nano, 2024, v.18 no.6, 4704-4716
    SCIE Scopus dColl.
  • Cannabidiol, a Regulator of Intracellular Calcium and Calpain Cannabis and Cannabinoid Research, 2023, v.8 no.1, 119-125
    Scopus dColl.
  • Cervi Parvum Cornu complex for men with lower urinary tract symptoms: a multicenter, randomized, double-blind, placebo-controlled trial Prostate International, 2023, v.11 no.4, 222-227
    SCIE Scopus dColl.
  • Design, synthesis, and biological evaluation of novel HSP27 inhibitors to sensitize lung cancer cells to clinically available anticancer agents Bioorganic Chemistry, 2023, v.130, 106260
    SCIE Scopus dColl.
  • Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure–activity relationships Bioorganic and Medicinal Chemistry, 2023, v.91, 117403
    SCIE Scopus dColl.
  • Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers Journal of Advanced Research, 2023, v.47, 173-187
    SCIE Scopus dColl.
  • Original Article BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner AMERICAN JOURNAL OF CANCER RESEARCH, 2023, v.13 no.12, 0
    SCIE Scopus dColl.
  • Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells European journal of medicinal chemistry, 2023, v.246, 114999
    SCIE Scopus dColl.
  • Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations Cellular Oncology, 2022, v.45 no.5, 913-930
    SCIE Scopus dColl.
  • An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGF beta R-1 LIFE-BASEL, 2022, v.12 no.11, 1764
    SCIE Scopus dColl.
  • Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-f]quinoline Derivatives Pharmaceuticals, 2022, v.15 no.4, 399
    SCIE Scopus dColl.
  • Discovery of (E)-3-(3-((2-Cyano-4' -dimethylaminobiphenyl-4-ylmethyl)cyclohexanecarbonylamino)-5-fluorophenyl)acrylic Acid Methyl Ester, an Intestine-Specific, FXR Partial Agonist for the Treatment of Nonalcoholic Steatohepatitis JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.65 no.14, 9974-10000
    SCIE Scopus dColl.
  • Epigenetic regulator Cfp1 safeguards male meiotic progression by regulating meiotic gene expression EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, v.54 no.8, 1098-1108
    SCIE Scopus KCI dColl.
  • Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R EMBO Reports, 2022, v.23 no.8, e52977
    SCIE Scopus dColl.
  • Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors European Journal of Medicinal Chemistry, 2022, v.227, 113916
    SCIE Scopus dColl.
  • The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, v.37 no.30, e235
    SCIE Scopus KCI dColl.
  • Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated 2,6-diphenyl-4-fluorophenylpyridines: Design, synthesis, and structure-activity relationships Bioorganic and Medicinal Chemistry Letters, 2022, v.60, 128606
    SCIE Scopus dColl.
  • Topologically-Interlocked Minicircles as Probes of DNA Topology and DNA-Protein Interactions Chemistry - A European Journal, 2022, v.28 no.22, e202200108
    SCIE Scopus dColl.
  • 4-Flourophenyl-substituted 5H-indeno[1,2-b]pyridinols with enhanced topoisomerase II alpha inhibitory activity: Synthesis, biological evaluation, and structure-activity relationships BIOORGANIC CHEMISTRY, 2021, v.116, 105349
    SCIE Scopus dColl.
  • Ak-i-190, a new catalytic inhibitor of topoisomerase ii with anti-proliferative and pro-apoptotic activity on androgen-negative prostate cancer cells International Journal of Molecular Sciences, 2021, v.22 no.20, 11246
    SCIE Scopus dColl.
  • An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma CANCERS, 2021, v.13 no.13, 3221
    SCIE Scopus dColl.
  • Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase II alpha BIOMOLECULES & THERAPEUTICS, 2021, v.29 no.5, 562-570
    SCIE Scopus KCI dColl.
  • COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development Archives of Pharmacal Research, 2021, v.44 no.5, 499-513
    SCIE Scopus KCI dColl.
  • Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase IIα poison European Journal of Medicinal Chemistry, 2021, v.226, 113860
    SCIE Scopus dColl.
  • Drug-like small molecule HSP27 functional inhibitor sensitizes lung cancer cells to gefitinib or cisplatin by inducing altered cross-linked Hsp27 dimers Pharmaceutics, 2021, v.13 no.5, 630
    SCIE Scopus dColl.
  • Identification of Indicators for Preterm Birth Using Retinoid Metabolites METABOLITES, 2021, v.11 no.7, 443
    SCIE Scopus dColl.
  • Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase IIα inhibitors Bioorganic Chemistry, 2021, v.111, 104884
    SCIE Scopus dColl.
  • Bacterial Nucleoside Catabolism Controls Quorum Sensing and Commensal-to-Pathogen Transition in the Drosophila Gut CELL HOST & MICROBE, 2020, v.27 no.3, 345-
    SCIE Scopus dColl.
  • Field-based rational design of p300 histone acetyltransferase inhibitor and systematic evaluation as an anti-fibrotic agent CHEMICAL COMMUNICATIONS, 2020, v.56 no.68, 9795-9798
    SCIE Scopus dColl.
  • Plumbagin Suppresses Pulmonary Fibrosis Via Inhibition of p300 Histone Acetyltransferase Activity JOURNAL OF MEDICINAL FOOD, 2020, v.23 no.6, 633-640
    SCIE Scopus KCI dColl.
  • Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance CANCERS, 2020, v.12 no.6, 1540
    SCIE Scopus dColl.
  • Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, v.20 no.4, 464-475
    SCIE Scopus dColl.
  • A chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform CHEMICAL COMMUNICATIONS, 2019, v.55 no.85, 12857-12860
    SCIE Scopus dColl.
  • Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II alpha-Targeted Chemotherapeutic Agents for Breast Cancer JOURNAL OF MEDICINAL CHEMISTRY, 2019, v.62 no.17, 8194-8234
    SCIE Scopus dColl.
  • Recent therapeutic trends and promising targets in triple negative breast cancer Pharmacology and Therapeutics, 2019, v.199, 30-57
    SCIE Scopus dColl.
  • The synthesis and anticancer activities of chiral epoxy-substituted chromone analogs Bioorganic Chemistry, 2019, v.84, 347-354
    SCIE Scopus dColl.
  • A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships BIOORGANIC & MEDICINAL CHEMISTRY, 2018, v.26 no.18, 5212-5223
    SCIE Scopus dColl.
  • Causes of hyperhomocysteinemia and its pathological significance ARCHIVES OF PHARMACAL RESEARCH, 2018, v.41 no.4, 372-383
    SCIE Scopus KCI dColl.
  • Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors European Journal of Medicinal Chemistry, 2018, v.143, 200-215
    SCIE Scopus dColl.
  • Design, synthesis, and structure-activity relationships of new benzofuro[3,2-b]pyridin-7-ols as DNA topoisomerase II inhibitors Bioorganic and Medicinal Chemistry Letters, 2018, v.28 no.4, 566-571
    SCIE Scopus dColl.
  • Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines BIOORGANIC CHEMISTRY, 2018, v.79, 1-18
    SCIE Scopus dColl.
  • Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/II alpha inhibitors BIOORGANIC & MEDICINAL CHEMISTRY, 2018, v.26 no.18, 5181-5193
    SCIE Scopus dColl.
  • Hyperactivated m-calpain affects acquisition of doxorubicin resistance in breast cancer cells Biochimica et Biophysica Acta - General Subjects, 2018, v.1862 no.5, 1126-1133
    SCIE Scopus dColl.
  • Intestinal P-glycoprotein inhibitors, benzoxanthone analogues JOURNAL OF PHARMACY AND PHARMACOLOGY, 2018, v.70 no.2, 234-241
    SCIE Scopus dColl.
  • Linear diarylheptanoids as potential anticancer therapeutics: synthesis, biological evaluation, and structure-activity relationship studies ARCHIVES OF PHARMACAL RESEARCH, 2018, v.41 no.12, 1131-1148
    SCIE Scopus KCI dColl.
  • Modification of translationally controlled tumor protein-derived protein transduction domain for improved intranasal delivery of insulin DRUG DELIVERY, 2018, v.25 no.1, 1025-1032
    SCIE Scopus dColl.
  • Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase II alpha-targeting anticancer agents BIOORGANIC & MEDICINAL CHEMISTRY, 2018, v.26 no.8, 1909-1919
    SCIE Scopus dColl.
  • 2-Chlorophenyl-substituted benzofuro[3,2-b] pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, v.27 no.15, 3279-3283
    SCIE Scopus dColl.
  • A novel indeno[1,2-b] pyridinone derivative, a DNA intercalative human topoisomerase II alpha catalytic inhibitor, for caspase 3-independent anticancer activity CHEMICAL COMMUNICATIONS, 2017, v.53 no.51
    SCIE Scopus dColl.
  • Antiepileptic and Neuroprotective Effects of Oleamide in Rat Striatum on Kainate-Induced Behavioral Seizure and Excitotoxic Damage via Calpain Inhibition FRONTIERS IN PHARMACOLOGY, 2017, v.8, 817
    SCIE Scopus dColl.
  • BMI-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death Oncology Reports, 2017, v.37 no.1, 579-586
    SCIE Scopus dColl.
  • Design, synthesis and biological evaluation of 1,3-diphenylbenzo[f] [1,7]naphthyrdines BIOORGANIC & MEDICINAL CHEMISTRY, 2017, v.25 no.20, 5586-5597
    SCIE Scopus dColl.
  • Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and II alpha dual inhibitors with DNA non-intercalative catalytic activity EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, v.133, 69-84
    SCIE Scopus dColl.
  • Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells European Journal of Medicinal Chemistry, 2017, v.125, 49-67
    SCIE Scopus dColl.
  • Novel 2-aryl-4-(4′-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors European Journal of Medicinal Chemistry, 2017, v.125, 14-28
    SCIE Scopus dColl.
  • Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor European Journal of Medicinal Chemistry, 2017, v.127, 318-333
    SCIE Scopus dColl.
  • Sensitization of lung cancer cells by altered dimerization of HSP27 Oncotarget, 2017, v.8 no.62, 105372-105382
    SCIE Scopus dColl.
  • Synthesis and biological effect of chrom-4-one derivatives as functional inhibitors of heat shock protein 27 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, v.139, 892-900
    SCIE Scopus dColl.
  • The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection Journal of Natural Products, 2017, v.80 no.8, 2379-2383
    SCIE Scopus dColl.
  • The synthesis of tamoxifen-loaded albumin nanoparticles by homogenizers: Optimization and in vitro characterization Journal of Drug Delivery Science and Technology, 2017, v.41, 20-30
    SCIE Scopus dColl.
  • A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study European Journal of Medicinal Chemistry, 2016, v.113, 228-245
    SCIE Scopus dColl.
  • Calcium influx-mediated translocation of m-calpain induces Ku80 cleavage and enhances the Ku80-related DNA repair pathway ONCOTARGET, 2016, v.7 no.21, 30831-30844
    SCIE Scopus dColl.
  • Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor Bioorganic and Medicinal Chemistry, 2016, v.24 no.8
    SCIE Scopus dColl.
  • Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, v.26 no.7, 1726-1731
    SCIE Scopus dColl.
  • MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation Oncology Reports, 2016, v.35 no.2, 1041-1048
    SCIE Scopus dColl.
  • Neuroprotective effect of synthetic chalcone derivatives as competitive dual inhibitors against μ-calpain and cathepsin B through the downregulation of tau phosphorylation and insoluble Aβ peptide formation European Journal of Medicinal Chemistry, 2016, v.121, 433-444
    SCIE Scopus dColl.
  • Overcoming HSP27-mediated resistance by altered dimerization of HSP27 using small molecules ONCOTARGET, 2016, v.7 no.33, 53178-53190
    SCIE Scopus dColl.
  • Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and. Heat Shock Protein 90 BIOMOLECULES & THERAPEUTICS, 2016, v.24 no.5, 453-468
    SCIE Scopus dColl.
  • Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents BIOORGANIC CHEMISTRY, 2016, v.66, 145-159
    SCIE Scopus dColl.
  • Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase II alpha catalytic inhibitors EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, v.123, 211-225
    SCIE Scopus dColl.
  • Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones BIOORGANIC & MEDICINAL CHEMISTRY, 2016, v.24 no.22, 5921-5928
    SCIE Scopus dColl.
  • A Series of Novel Terpyridine-Skeleton Molecule Derivants Inhibit Tumor Growth and Metastasis by Targeting Topoisomerases JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.58 no.3, 1100-1122
    SCIE Scopus dColl.
  • Benzo[b]Tryptanthrin Inhibits MDR1, Topoisomerase Activity, and Reverses Adriamycin Resistance in Breast Cancer Cells ChemMedChem, 2015, v.10 no.5, 827-835
    SCIE Scopus dColl.
  • Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents Bioorganic and Medicinal Chemistry, 2015, v.23 no.19, 6454-6466
    SCIE Scopus dColl.
  • Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity Bioorganic and Medicinal Chemistry, 2015, v.23 no.1, 160-173
    SCIE Scopus dColl.
  • Modification of 3-arylisoquinolines into 3,4-diarylisoquinolines and assessment of their cytotoxicity and topoisomerase inhibition European Journal of Medicinal Chemistry, 2015, v.92, 583-607
    SCIE Scopus dColl.
  • Modified 2,4-diaryl-5H-indeno[1,2-b]pyridines with hydroxyl and chlorine moiety: Synthesis, anticancer activity, and structure-activity relationship study Bioorganic Chemistry, 2015, v.62, 30-40
    SCIE Scopus dColl.
  • Substituted 2-arylquinazolinones: Design, synthesis, and evaluation of cytotoxicity and inhibition of topoisomerases European Journal of Medicinal Chemistry, 2015, v.103, 69-79
    SCIE Scopus dColl.
  • Synthesis and biological activity of 2,4-di- p -phenolyl-6- 2 -furanyl-pyridine as a potent topoisomerase II poison European Journal of Medicinal Chemistry, 2015, v.90, 360-378
    SCIE Scopus dColl.
  • Synthesis and in vitro screening of phenylbipyridinylpyrazole derivatives as potential antiproliferative agents Molecules, 2015, v.20 no.1, 1031-1045
    SCIE Scopus dColl.
  • Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines Bioorganic and Medicinal Chemistry, 2015, v.23 no.13
    SCIE Scopus dColl.
  • Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines Bioorganic and Medicinal Chemistry, 2015, 2015
    SCIE Scopus dColl.
  • Xanthone analogues as potent modulators of intestinal P-glycoprotein EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, v.93, 237-245
    SCIE Scopus dColl.
  • sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1 alpha signaling pathways ONCOTARGET, 2015, v.6 no.31, 31830-31843
    SCIE Scopus dColl.
  • Cobalt-albumin binding (CAB) assay: An advantageous and flaw free testing of albumin-cobalt binding Journal of Pharmaceutical and Biomedical Analysis, 2014, v.99, 79-82
    Scopus dColl.
  • Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors European Journal of Medicinal Chemistry, 2014, v.82, 181-194
    Scopus SCIE dColl.
  • Development of an Albumin Copper Binding (ACuB) Assay to Detect Ischemia Modified Albumin ANALYTICAL SCIENCES, 2014, v.30 no.10, 985-990
    SCIE Scopus dColl.
  • Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl-pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.80 no., 428-438
    SCIE Scopus dColl.
  • Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3, 2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor BIOORGANIC & MEDICINAL CHEMISTRY, 2014, v.22 no.17, 4553-4565
    SCIE Scopus dColl.
  • Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, v.91, 17-23
    SCIE Scopus dColl.
  • Fluorescein Hydrazones as Novel Nonintercalative Topoisomerase Catalytic Inhibitors with Low DNA Toxicity JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.57 no.21, 9139-9151
    SCIE dColl.
  • Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase catalytic inhibitor European Journal of Medicinal Chemistry, 2014, v.90, 302-314
    SCIE Scopus dColl.
  • Reply to the Letter to the Editor "Cobalt-albumin binding (CAB) assay: An advantageous and flaw free testing of albumin-cobalt binding" JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, v.99, 81-82
    SCIE Scopus dColl.
  • Synthesis, antitumor,activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, v.84, 555-565
    SCIE Scopus dColl.
  • [학술지논문] Cannabidiol, a Regulator of Intracellular Calcium and Calpain CANNABIS AND CANNABINOID RESEARCH , 2023, v.11 no.111 , 1-7
    SCIE
  • [학술지논문] Design, synthesis, and biological evaluation of novel HSP27 inhibitors to sensitize lung cancer cells to clinically available anticancer agents BIOORGANIC CHEMISTRY, 2023, v.130 no.1062600 , 1-11
    SCIE
  • [학술지논문] Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships BIOORGANIC & MEDICINAL CHEMISTRY, 2023, v.91 no.117403 , 1-12
    SCIE
  • [학술지논문] Editorial: Small organic molecules with anticancer activity FRONTIERS IN CHEMISTRY, 2023, v.11 no.2023 , 1-2
    SCIE
  • [학술지논문] Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers JOURNAL OF ADVANCED RESEARCH, 2023, v.47 no.0 , 173-187
    SCIE
  • [학술지논문] Original Article BR101801 enhances the radiosensitivity of p53-deficient colorectal cancer cells by inducing G2/M arrest, apoptosis, and senescence in a p53-independent manner AMERICAN JOURNAL OF CANCER RESEARCH, 2023, v.13 no.12 , 5887-5900
    SCIE
  • [학술지논문] Roles of Coffee and Its Components in Liver Diseases Drug Targets and Therapeutics, 2023, v.2 no.2 , 133-144
    KCI
  • [학술지논문] Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, v.246 no.114999 , 1-16
    SCIE
  • [학술지논문] An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGF beta R-1 LIFE-BASEL, 2022, v.12 no.11 , 1764-1764
    SCIE
  • [학술지논문] Design, Synthesis, and Cytotoxicity and Topoisomerase I/IIα Inhibition Activity of Pyrazolo[4,3-f]quinoline Derivatives Pharmaceuticals, 2022, v.15 no.4 , 399-399
    SCIE
  • [학술지논문] Epigenetic regulator Cfp1 safeguards male meiotic progression by regulating meiotic gene expression EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, v.54 no.8 , 1098-1108
    SCI
  • [학술지논문] Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R EMBO REPORTS, 2022, v.23 no.8 , 52977-52977
    SCI
  • [학술지논문] Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, v.227 no.2022 , 113916-113934
    SCI
  • [학술지논문] The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, v.37 no.30 , 235-235
    SCI
  • [학술지논문] Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated 2,6-diphenyl-4-fluorophenylpyridines: Design, synthesis, and structure-activity relationships BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, v.60 no.0 , 128606-128606
    SCI
  • [학술지논문] Topologically-Interlocked Minicircles as Probes of DNA Topology and DNA-Protein Interactions CHEMISTRY-A EUROPEAN JOURNAL, 2022, v.28 no.22 , 202200108-202200108
    SCI
  • [학술지논문] 4-Flourophenyl-substituted 5H-indeno[1,2-b]pyridinols with enhanced topoisomerase II alpha inhibitory activity: Synthesis, biological evaluation, and structure-activity relationships BIOORGANIC CHEMISTRY, 2021, v.116 no.2021 , 105349-105360
    SCI
  • [학술지논문] AK-I-190, a New Catalytic Inhibitor of Topoisomerase II with Anti-Proliferative and Pro-Apoptotic Activity on Androgen-Negative Prostate Cancer Cells INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, v.22 no.20 , 11246-11246
    SCIE
  • [학술지논문] An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma CANCERS, 2021, v.13 no.13 , 3221-3246
    SCIE
  • [학술지논문] Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase II alpha BIOMOLECULES & THERAPEUTICS, 2021, v.29 no.5 , 562-570
    SCIE
  • [학술지논문] COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development ARCHIVES OF PHARMACAL RESEARCH, 2021, v.44 no.5 , 499-513
    SCIE
  • [학술지논문] Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase II alpha poison EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, v.226 no.0 , 113860-113860
    SCI
  • [학술지논문] Drug-Like Small Molecule HSP27 Functional Inhibitor Sensitizes Lung Cancer Cells to Gefitinib or Cisplatin by Inducing Altered Cross-Linked Hsp27 Dimers PHARMACEUTICS, 2021, v.13 no.5 , 630-649
    SCIE
  • [학술지논문] Identification of Indicators for Preterm Birth Using Retinoid Metabolites METABOLITES, 2021, v.11 no.7 , 443-443
    SCIE
  • [학술지논문] Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase II alpha inhibitors BIOORGANIC CHEMISTRY, 2021, v.111 no.2021 , 104884-104898
    SCI
  • [학술지논문] Bacterial Nucleoside Catabolism Controls Quorum Sensing and Commensal-to-Pathogen Transition in the Drosophila Gut CELL HOST & MICROBE, 2020, v.27 no.3 , 345-345
    SCI
  • [학술지논문] Field-based rational design of p300 histone acetyltransferase inhibitor and systematic evaluation as an anti-fibrotic agent CHEMICAL COMMUNICATIONS, 2020, v.56 no.68 , 9795-9798
    SCI
  • [학술지논문] Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance CANCERS, 2020, v.12 no.6 , 1-24
    SCIE
  • [학술지논문] Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, v.20 no.4 , 464-475
    SCIE
  • [학술지논문] Recent therapeutic trends and promising targets in triple negative breast cancer PHARMACOLOGY & THERAPEUTICS, 2019, v.199 no.0 , 30-57
    SCI
  • [학술지논문] The synthesis and anticancer activities of chiral epoxy-substituted chromone analogs BIOORGANIC CHEMISTRY, 2019, v.84 no.2019 , 347-354
    SCI
  • [저역서] 의약품기기분석학 동명사, 2023, 496
  • [학술발표] Oncogenic Protein and Its Protein-Protein Interactions: Drug Targetability and Overcoming Therapeutic Resistance Strategies 2023 Annual Meeting and Symposium of The Korea Society of Applied Pharmacology, 대한민국, 2023-10-06 Exploring Novel Therapeutic Approaches for Intractable Diseases through Organoid Models, 2023
  • [학술발표] Targeting the oncogenic role of E74 Like ETS transcription factor 3 (ELF3) through modulation of its protein-protein interaction Targeting the oncogenic role of E74 Like ETS transcription factor 3 (ELF3) through modulation of its, 대한민국, 2023-10-26 Exploring the Frontiers of Pharmaceutical Sciences, 2023
  • [지적재산권] 할로겐 함유 2,4-디페닐 인데노피리딘-5-온 유도체 및 이의 제조방법 Domestic : Patent , Registration , 10-2629173, 2024
  • [지적재산권] 신규 화합물 및 그를 유효성분으로 포함하는 약학 조성물 Domestic : Patent , Registration , 10-2409583, 2022
Courses
  • 2024-2nd

    • Pharmaceutical Instrumental Analysis

      • Subject No 37130Class No 01
      • 4Year ( 3Credit , 3Hour) Mon 2~2 (PHM-A104) , Tue 4~4 (PHM-A400)
    • Pharmaceutical Instrumental Analysis

      • Subject No 37130Class No 02
      • 4Year ( 3Credit , 3Hour) Mon 4~4 (POSCO551) , Wed 2~2 (PHM-A404)
    • Pharmaceutical Analysis Ⅱ

      • Subject No 39043Class No 01
      • 2Year ( 3Credit , 3Hour) Mon 5~5 (POSCO551) , Tue 2~2 (PHM-A404)
      • Major Requisite
  • 2023-2nd

  • 2023-1st

  • 2022-2nd

    • Pharmaceutical Analysis II

      • Subject No 33963Class No 01
      • 3Year ( 3Credit , 3Hour) Mon 2~2 (PHM-A400) , Wed 3~3 (PHM-A404)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 01
      • 3Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 02
      • 3Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 03
      • 3Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Instrumental Analysis

      • Subject No 37130Class No 01
      • 4Year ( 3Credit , 3Hour) Mon 4~4 (PHM-A404) , Tue 2~2 (PHM-A104)
    • Lab rotation Ⅰ

      • Subject No 38927Class No 01
      • 1Year ( 1.5Credit , 0Hour) Thu 7~7
    • Lab rotation Ⅰ

      • Subject No 38927Class No 02
      • 1Year ( 1.5Credit Thu 7~7
    • Lab rotation Ⅰ

      • Subject No 39032Class No 01
      • 1Year ( 1.5Credit , 0Hour) Thu 7~7
  • 2022-1st

    • Pharmaceutical Analysis I

      • Subject No 33502Class No 01
      • 3Year ( 3Credit , 3Hour) Mon 2~2 (PHM-A100-1) , Wed 2~2 (PHM-A400)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 01
      • 3Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 02
      • 3Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 03
      • 3Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A300)
      • Major Requisite
    • Seminar for Pharmaceutical Sciences III

      • Subject No G16849Class No 01
      • Year ( 3Credit , 3Hour) Thu 7~8 (-)
    • Seminar for Pharmaceutical Sciences Ⅲ

      • Subject No G18240Class No 01
      • Year ( 3Credit , 3Hour) Thu 7~8 (-)
  • 2021-2nd

    • Pharmaceutical Analysis II

      • Subject No 33963Class No 01
      • 3Year ( 3Credit , 3Hour) Mon 3~3 , Wed 3~3
      • Major Requisite
    • Pharmaceutical Analysis II

      • Subject No 33963Class No 02
      • 3Year ( 3Credit , 3Hour) Mon 5~5 , Wed 4~4
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 01
      • 3Year ( 1.5Credit , 3Hour) Mon 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 02
      • 3Year ( 1.5Credit , 3Hour) Tue 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 03
      • 3Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 04
      • 3Year ( 1.5Credit , 3Hour) Wed 6~9 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Instrumental Analysis

      • Subject No 37130Class No 01
      • 4Year ( 3Credit , 3Hour) Mon 4~4 , Thu 3~3
    • Pharmaceutical Instrumental Analysis

      • Subject No 37130Class No 02
      • 4Year ( 3Credit , 3Hour) Tue 5~5 , Thu 4~4
    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 01
      • 6Year ( 4Credit
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
  • 2021-1st

    • Pharmaceutical Analysis I

      • Subject No 33502Class No 01
      • 3Year ( 3Credit , 3Hour) Mon 2~2 , Wed 3~3
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 01
      • 3Year ( 1.5Credit , 3Hour) Tue 6~7 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 02
      • 3Year ( 1.5Credit , 3Hour) Mon 6~7 (PHM-A300)
      • Major Requisite
    • Pharmaceutical Experiment I

      • Subject No 37105Class No 03
      • 3Year ( 1.5Credit , 3Hour) Wed 6~7 (PHM-A300)
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
Work Experience

Director, Drug Development Research Core Center 2021-12-01 ~ 2025-07-31